tbuckley/cabot-search huggingface dataset:
Colchicine: an ancient drug with novel applications
Authors: B. Dasgeb, D. Kornreich, K. McGuinn, L. Okon, I. Brownell, D.L. Sackett
Journal: British Journal of Dermatology (2018)

Colchicine is one of the oldest remedies still in use today. It is derived from the bulb‐like corms of the Colchicum autumnale plant, also known as autumn crocus. Its history as an herbal remedy for joint pain goes back at least a thousand years, and it is used to treat disorders including gout and Familial Mediterranean Fever. Despite this, exactly how colchicine works is still being explored. More recently, colchicine has been reported to be an effective treatment for several skin diseases, including Behçet's disease, epidermolysis bullosa acquisita, leukocytocastic vasculitis, Sweet's syndrome and recurrent apthous stomatitis. However, the existing research often relates to small numbers of patients. This review, by scientists in the U.S.A., outlines the existing research into a list of skin diseases, and provides a table to show the level of evidence for each one. A number of skin diseases have already been found to respond to colchicine, and more thorough studies will likely reveal new uses for this ancient drug.
HUMAN STERILIZATION
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Leisure Corner
Journal: JAMA (1974)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Interferon treatment of chronic active hepatitis C during therapy of acute lymphoblastic leukemia
Authors: Peter Waldron
Journal: American Journal of Hematology (1999)

Due to concerns that antineoplastic therapy produces prolonged decrease in immune function, interferon treatment of chronic active hepatitis C (CAHC) has been used only at one year or longer after the end of cancer therapy. We report the experience of an 11-year-old who developed symptomatic CAHC at the start of maintenance therapy for testicular relapse of acute lymphoblastic leukemia (ALL). Significant dose reduction of maintenance therapy did not improve the tolerance of antileukemic treatment. In an effort to improve his liver disease and to deliver effective antileukemic therapy, interferon alpha and an alternative maintenance therapy regimen for ALL were initiated. The patient tolerated the combined therapy well. Interferon therapy was continued for 27 months, which was three months from the end of antineoplastic therapy. At that time serum transaminase values were normal, and no HCV viral genome was detectable. Viral genome was detected 10 months later. The combined effects of interferon and antineoplastic therapy resulted in myelosuppression requiring dose reduction of both treatments. The patient remains asymptomatic and with no evidence of recurrent leukemia more than six years from diagnosis of relapse. The effect on the status of this patient's CAHC was similar to that reported among leukemic patients who underwent an interferon course more than one year from the end of antineoplastic therapy. Interferon treatment of CAHC can be given concomitantly with antineoplastic therapy. Am. J. Hematol. 61:130–134, 1999. © 1999 Wiley-Liss, Inc.
Vesicular Eruption
Authors: Robert K. Sylvester
Journal: JAMA (1986)

THE ANTIVIRAL agent acyclovir is effective in preventing progression of herpes zoster in immunocompromised patients.<sup>1-3</sup>The following case report describes an immunocompromised patient who developed vesicles at three different intravenous (IV) acyclovir sites. A review of the literature and the package insert provided by Burroughs Wellcome Co failed to document previous similar occurrences.<sup>4</sup> <h3>Report of a Case</h3> A 60-year-old man came to the emergency department with a three-day history of left-sided facial pain associated with an erythematous vesicular eruption involving the maxillary division of the trigeminal nerve. No ocular involvement was noted. His medical history included chronic lymphocytic leukemia treated with splenectomy and chlorambucil and prednisone. A diagnosis of herpes zoster was made and, because of the proximity of the lesion to the eye and his underlying lymphoproliferative disease, he was admitted to the hospital for IV acyclovir sodium. On the first day of therapy he received
Minimum Standards for the Commercial Production of Randombred and Inbred Laboratory Mice (Revised September 22, 1957)&lt;xref ref-type="fn" rid="FN1"&gt;1&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Journal: JNCI Journal of the National Cancer Institute (1957)

Journal Article Minimum Standards for the Commercial Production of Randombred and Inbred Laboratory Mice (Revised September 22, 1957) Get access JNCI: Journal of the National Cancer Institute, Volume 19, Issue 6, December 1957, Pages 1137–1143, https://doi.org/10.1093/jnci/19.6.1137 Published: 01 December 1957
The Fate of Airborne Polycyclic Organic Matter
Authors: Torben Nielsen, Thomas Ramdahl, Alf Bjorseth
Journal: Environmental Health Perspectives (1983)

Biological tests have shown that a significant part of the mutagenicity of organic extracts of collected airborne particulate matter is not due to polycyclic aromatic hydrocarbons (PAH). It is possible that part of these unknown compounds are transformation products of PAH. This survey focuses on the reaction of PAH in the atmosphere with other copollutants, such as nitrogen oxides, sulfur oxides, ozone and free radicals and their reaction products. Photochemically induced reactions of PAH are also included. The reactivity of particle-associated PAH is discussed in relation to the chemical composition and the physical properties of the carrier. Recommendations for future work are given.
Newspaper Reporting of Screening Mammography
Authors: Joel G. Ray
Journal: Annals of Internal Medicine (2002)

Letters3 September 2002Newspaper Reporting of Screening MammographyJoel G. Ray, MD, FRCPC, MScJoel G. Ray, MD, FRCPC, MScSunnybrook and Women's College Health Sciences Centre; Toronto, Ontario M6P 2N6, CanadaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-5_Part_1-200209030-00033 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Wells and colleagues (1) recommend that “some basic criteria for medical journalism could be identified,” such as “disclosing sources' possible conflicts of interest [and] the type of evidence on which assertions and recommendations are based” and “fram[ing] benefit in absolute as well as relative terms” (1). In 1997, three academic internists from McMaster University in Hamilton, Ontario, Canada; five Canadian health reporters; and the dean of one of Canada's schools of journalism met to generate these very critreia, which were published in the American Medical Writers Association Journal (2). These guidelines were based on several meetings held ...References1. Wells J, Marshall P, Crawley B, Dickersin K. Newspaper reporting of screening mammography. Ann Intern Med. 2001;135:1029-37. [PMID: 11747381] LinkGoogle Scholar2. Guyatt G, Ray JG, Gibson N, Taylor P, Spencer D, Engel J, et al . Guidelines for health reporters. American Medical Writers Association Journal. 1998;14:32-42. Google Scholar3. Shuchman M, Wilkes MS. Medical scientists and health news reporting: a case of miscommunication. Ann Intern Med. 1997;126:976-82. [PMID: 9182476] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Sunnybrook and Women's College Health Sciences Centre; Toronto, Ontario M6P 2N6, Canada PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoNewspaper Reporting of Screening Mammography Jane Wells , Phillip Marshall , Barbara Crawley , and Kay Dickersin Newspaper Reporting of Screening Mammography Michael Rosen Newspaper Reporting of Screening Mammography Michael Rosen Metrics 3 September 2002Volume 137, Issue 5_Part_1Page: 374KeywordsConflicts of interestHealth information technologyMammographyPrevention, policy, and public health ePublished: 3 September 2002 Issue Published: 3 September 2002 CopyrightCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
The Story of the Bacteria and their Relation to Health and Disease.
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chemoreceptors of Crustaceans: Similarities to Receptors for Neuroactive Substances in Internal Tissues
Authors: William E. S. Carr, Barry W. Ache, Richard A. Gleeson
Journal: Environmental Health Perspectives (1987)

A description is given of crustacean chemosensory systems and the neurophysiological procedures used to study them. Their response properties and tuning characteristics are discussed. A review is then provided of specific crustacean chemoreceptors that are stimulated selectively by either purine nucleotides, taurine, glutamate, or glycine, all of which have neuroactive properties in internal tissues. Two distinctly different types of purinergic chemoreceptors occur on the antennules of the spiny lobster. P1-like chemoreceptors have a potency sequence of AMP greater than ADP greater than ATP greater than adenosine and show a strict structural requirement for the ribose phosphate moiety. P2-like chemoreceptors have a potency sequence of ATP greater than ADP greater than AMP or adenosine and show a broad sensitivity to nucleotide triphosphates with modifications in both the purine and ribose phosphate moieties. Sensilla containing the dendrites of chemosensory neurons also possess an ectonucleotidase(s) that inactivates excitatory nucleotides to yield adenosine which is subsequently internalized by a sensillar uptake system. Narrowly tuned taurinergic chemoreceptors are present on both the antennules and legs of lobsters. Although taurine itself is the most effective stimulant, the taurine analogs hypotaurine and beta-alanine are also very excitatory. Structure-activity studies indicate these chemoreceptors have marked similarities to taurine-sensitive systems in internal tissues of vertebrates. By contrast, comparative studies of glutamatergic chemoreceptors on the legs of lobsters indicate response spectra different from those of the glutamate receptors in lobster neuromuscular junctions and the three classes of excitatory amino acid receptors identified internally in vertebrates. Crustacean chemoreceptors for glycine, ecdysteroids, and pyridine are also described. The hypothesis that receptors for internal neuroactive agents may have originally evolved as external chemoreceptors of primitive aquatic organisms is discussed.
Abstract 4580: Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model
Authors: Raziye Piranlioglu, Eunmi Lee, Maria Ouzuonova, Riley Rodier, Adam Greer, Feyzanur Bayraktar, Omer Can Durmus, Ali S. Arbab, Muthushamy Thangaraju, Max S. Wicha, Esteban Celis, Hasan Korkaya
Journal: Cancer Research (2019)

Abstract Although clinically apparent metastasis is associated with late stages of cancer development, micro-metastatic dissemination may be an early event. However, the fate of these early disseminated tumor cells (DTC) remains elusive. Using the syngeneic mouse models, we demonstrated that although both orthotopically-implanted murine 4T1 and EMT6 tumors are capable of disseminating into secondary organs, only 4T1 tumors develop overt metastasis. However, EMT6 tumors induce an anti-tumor immunity in syngeneic mice and that eradicates disseminated tumor cells (DTC) in distant organs. Following the complete removal of primary EMT6 tumors, mice do not develop detectable metastasis and generate an immunological memory that leads to complete elimination of repeatedly injected tumor cells via tail vein. Conversely, these cells readily grow and metastasize in immuno-deficient athymic or Rag2- mice, and when g-MDSCs from 4T1 tumor-bearing mice were co-injected into immunocompetent EMT6 primed mice. In contrast to complete resection, mice with residual tumors following surgery exhibited an enhanced growth of local and concomitant growth of DTCs at metastatic site with increased g-MDSCs accumulation in lung and spleen. Together, our results suggest that some tumors are capable of inducing anti-tumor immunity against the DTCs when complete resection of primary tumor cures animals. However, in the presence of residual tumors, inflammation induced by surgical procedure promote the growth of DTCs. Citation Format: Raziye Piranlioglu, Eunmi Lee, Maria Ouzuonova, Riley Rodier, Adam Greer, Feyzanur Bayraktar, Omer Can Durmus, Ali S. Arbab, Muthushamy Thangaraju, Max S. Wicha, Esteban Celis, Hasan Korkaya. Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4580.
Appointment as School Health Director in Utah.
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOK REVIEWS
Authors: R. B. ALEXANDER
Journal: JNCI Journal of the National Cancer Institute (1990)

BOOK REVIEWS Get access Tumor Necrosis Factor: Structure, Mechanism of Action, Role in Disease and Therapy . Benjamin Bonavida , Gale Granger , eds. Basel : Karger , 1990 , 252 pp. $ 132. RICHARD B. ALEXANDER RICHARD B. ALEXANDER National Cancer Institute Bldg10, Rm 2B56 Bethesda, MD 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 82, Issue 18, 19 September 1990, Page 1506, https://doi.org/10.1093/jnci/82.18.1506 Published: 19 September 1990
Abstract 1510: Androgen regulated IL-8 expression in prostate cancer: Insights into tumor cell mediated immunosuppression
Authors: Zoila A. Lopez Bujanda, Michael C. Haffner, Matthew G. Chaimowitz, Nivedita Chowdhury, Paula J. Hurley, Angela M. Christiano, Charles G. Drake
Journal: Cancer Research (2019)

Abstract Androgen deprivation therapy (ADT) results in castration-resistant prostate cancer (CRPC) in a significant fraction of patients. We have previously reported that the protein levels of interleukin-8 (IL-8) were inversely correlated with disease progression in men with biochemical recurrent prostate cancer treated with Lenalidomide. Recently, polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) were implicated as potential drivers of CRPC. Here we show that IL-8 expression is upregulated as a consequence of ADT and mediates the recruitment of PMN-MDSCs to the tumor microenvironment. We found that IL-8 expression is regulated by both an inflammatory stimulus (NF-kβ mediated) and loss of androgen receptor (AR) signaling following ADT. We confirmed direct binding of both the p65 subunit of NF-kβ and AR to the IL-8 promoter, and their respective effects on promoter activity. The suppressive activity of AR was further supported by a reduction in active transcription markers at the chromatin level surrounding the IL-8 promoter. Accordingly, intratumoral infiltration of PMN-MDSCs correlated with IL-8 expression, and was reduced in IL-8 knockouts. Taken together, these results suggest an innate inflammatory response, loss of AR suppressive activity, and subsequent chemokine upregulation as a potential mechanism that regulates the infiltration of PMN-MDSCs to the tumor microenvironment of CRPC after ADT. These findings open a window of opportunity for therapeutic interventions aiming to improve responses to checkpoint blockade in prostate cancer. Citation Format: Zoila A. Lopez Bujanda, Michael C. Haffner, Matthew G. Chaimowitz, Nivedita Chowdhury, Paula J. Hurley, Angela M. Christiano, Charles G. Drake. Androgen regulated IL-8 expression in prostate cancer: Insights into tumor cell mediated immunosuppression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1510.
Maternity services.
Authors: P. Sackin
Journal: BMJ (1992)

vivors were interviewed about the advice they had been given during and after their admission concerning smoking, diet, and exercise.When appropriate, patients were asked whether the result of serum cholesterol estimation had been discussed with them.Results were analysed with the xI test with Yates's correction.There were 142 eligible admissions (85 men).Thirty patients died before interview, and 17 refused consent or had dementia.The 95 subjects (58 men) interviewed had a median-age of75 (range 70-86) and were interviewed a median of8-6 (range 2 6-14) months after admisson.-Fifteenhad regularly smoked cigarettes.Twelve had been advised to stop and 11 had either done so or cut down considerably.One of the three with whom
in vivo metabolism and genotoxic effects of nitrated polycyclic aromatic hydrocarbons
Authors: L Möller
Journal: Environmental Health Perspectives (1994)

During incomplete combustion of organic matter, nitro-polycyclic aromatic hydrocarbons (nitro-PAHs), are formed in a reaction that is catalyzed by a low pH. 2-Nitrofluorene (NF), a marker for nitro-PAHs, is metabolized in vivo by two different routes.After inhalation, potent mutagenic metabolites, hydroxylated nitrofluorenes (OH-NFs), are formed.The metabolites are distributed by systemic circulation.After oral administration, NF is reduced to the corresponding amine, a reaction mediated by the intestinal microflora.This metabolite is acetylated to 2-acetylaminofluorene (AAF), a potent carcinogen.Further ring-hydroxylation of AAF leads to detoxification and excretion.Induction of cytochrome P450s affects the metabolism, and more OH-NFs are formed.As a consequence, more mutagenic metabolites are found in the circulation.OH-NFs are excreted in the bile as, in terms of mutagenicity, totally harmless glucuronide conjugates.When these conjugates are excreted via the bile, intestinal )-glucuronidase can liberate direct-acting mutagens in the intestine.Thus, inhalation of NF can lead to formation of potent mutagens in the intestine.NF is a direct-acting muta- gen in bacterial assays and an initiator and promoter of the carcinogenic process, and gives rise to DNA adduct formation in laboratory animals.-